QualityStocks would like to highlight
International Stem Cell Corporation (
OTCBB: ISCO), focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs).
In the company’s news,
International Stem Cell is successfully leveraging its parthenogenetic technology with its Lifeline Skin Care subsidiary. On the Lifeline Skin Care website (www.LifelineSkinCare.com) it says “Someday, stem cells will change the world. Today, stem cells will change your skin.” Lifeline Skin Care produces stem cell based skin care products, using technology only available through its association with ISCO. Although the application of stem cells and their regeneration properties to skin rejuvenation has been heavily popularized, Lifeline Skin Care’s offerings are unique.
Specifically, Lifeline stem cell creams are the only products in the world that contain human, non-embryonic stem cell extracts. This is possible because of ISCO’s development of parthenogenesis, the ability to generate true pluripotent stem cells without the use of a fertilized human embryo. It’s a one-of-a-kind technology that not only avoids the ethical issues common to stem cell application, but also results in stem cells that can be immune-matched to millions of people, avoiding the use of immuno-suppression drugs. ISCO scientists are focused on using these stem cells to treat severe diseases of the eye, the nervous system, and the liver, where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells.
Lifeline skin care is focused on the application of this technology to skin rejuvenation, combining stem cell biology, nanotechnology, and skin cream formulation technology to produce the highest quality, scientifically tested, and most effective anti-aging products available. The company does not license the brand name, the technology, the stem cell extracts, or proprietary ingredients to any other company. Moreover, revenues from Lifeline Skin Care help fund stem cell research for curing regenerative diseases like diabetes and Parkinson’s Disease.
However, to end users, the real life effectiveness of the product is most important, and is backed up by an independent clinical study showing 63% improved skin tone and brightness, 67% decreased wrinkles appearance, 73% increased skin elasticity, and 93% improved skin hydration.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit
www.QualityStocks.com
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
